2'-methyl-5'-(5-methyl-[1,3,4]oxadiazol-2-yl)-biphenyl-4-carboxylic acid (3-cyano-phenyl)-amide | 515152-78-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2'-methyl-5'-(5-methyl-[1,3,4]oxadiazol-2-yl)-biphenyl-4-carboxylic acid (3-cyano-phenyl)-amide
• 英文别名: N-(3-Cyanophenyl)-2'-Methyl-5'-(5-Methyl-1,3,4-Oxadiazol-2-Yl)-4-Biphenylcarboxamide；N-(3-cyanophenyl)-4-[2-methyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]benzamide
• CAS: 515152-78-0
• 化学式: C₂₄H₁₈N₄O₂
• 分子量: 394.433
• InChiKey: PMMLSQFPBFKLHH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  91.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carbonyl chloride 、 间氨基苯甲腈 在 三乙胺 作用下， 生成 2'-methyl-5'-(5-methyl-[1,3,4]oxadiazol-2-yl)-biphenyl-4-carboxylic acid (3-cyano-phenyl)-amide
  参考文献：
  名称：

  Biphenyl amide p38 kinase inhibitors 2: Optimisation and SAR

  摘要：

  The biphenyl amides are a novel series of p38 MAP kinase inhibitors. Structure-activity relationships of the series against p38 alpha are discussed with reference to the X-ray crystal structure of an example. The series was optimised rapidly to a compound showing oral activity in an in vivo disease model. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.10.043

文献信息

• Negishi Cross-Couplings Compatible with Unprotected Amide Functions
  作者：Georg Manolikakes、M.Sc. Zhibing Dong、Herbert Mayr、Jinshan Li、Paul Knochel

  DOI：10.1002/chem.200802349

  日期：2009.1.26

  Mild mannered: Unprotected amides and sulfonamides containing aryl bromides and iodides undergo, in the presence of S‐PHOS, smooth Negishi cross‐couplings with various zinc organometallic reagents, allowing the preparation of pharmaceutically relevant molecules (see scheme; S‐PHOS=2‐dicyclohexylphosphino‐2′,6′‐dimethoxybiphenyl).

  温和的态度：在S‐PHOS存在下，未保护的包含芳基溴化物和碘化物的酰胺和磺酰胺会与各种锌有机金属试剂进行平滑的Negishi交叉偶联，从而可制备药学上相关的分子（参见方案; S‐PHOS = 2‐二环己基膦基2'，6'-二甲氧基联苯）。
• 2'-Methyl-5-(1,3,4-oxadiazol-2-yl)1,1'-biphenyl-4-carboxaide derivatives and their use as p38 kinase inhibitors
  申请人：——

  公开号：US20040266839A1

  公开（公告）日：2004-12-30

  Compounds of formula (I), wherein R 1 is a phenyl group which may be optionally substituted; R 2 is selected from hydrogen, C 1-6 alkyl and (CH 2 ) p —C 3-7 cycloalkyl; R 3 is the group: (Formula II), R 4 is selected from hydrogen and C 1-4 alkyl; U is selected from methyl and halogen; X and Y are each selected independently from hydrogen, methyl and halogen; m is selected from 0, 1, 2, 3 and 4, and may be optionally substituted with up to two groups selected independently from C 1-6 alkyl; n is selected from 0, 1 and 2; p is selected from 0, 1 and 2; or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors. 1

  公式（I）的化合物，其中R1是苯基，可以选择性地被取代；R2选自氢、C1-6烷基和(CH2)p-C3-7环烷基；R3是基团：（公式II），R4选自氢和C1-4烷基；U选自甲基和卤素；X和Y各自独立地选自氢、甲基和卤素；m选自0、1、2、3和4，并且可以选择性地被最多两个独立选择自C1-6烷基的基团取代；n选自0、1和2；p选自0、1和2；或其药学上可接受的盐或溶剂，以及它们作为药物的用途，特别是作为p38激酶抑制剂。
• 2′-Methyl-5-(1,3,4-oxadiazol-2-yl)1, 1′-biphenyl-4-carboxaide derivatives and their use as p38 kinase
  申请人：Glaxo Group Limited

  公开号：US07384963B2

  公开（公告）日：2008-06-10

  Compounds of formula (I), wherein R1 is a phenyl group which may be optionally substituted; R2 is selected from hydrogen, C1-6 alkyl and (CH2)p—C3-7cycloalkyl; R3 is the group: (Formula II), R4 is selected from hydrogen and C1-4 alkyl; U is selected from methyl and halogen; X and Y are each selected independently from hydrogen, methyl and halogen; m is selected from 0, 1, 2, 3 and 4, and may be optionally substituted with up to two groups selected independently from C1-6 alkyl; n is selected from 0, 1 and 2; p is selected from 0, 1 and 2; or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors

  化合物的公式（I），其中R1是苯基，可以选择性地被取代; R2选自氢，C1-6烷基和（CH2）p-C3-7环烷基; R3是基团：（公式II），R4选自氢和C1-4烷基; U选自甲基和卤素; X和Y各自独立地选自氢，甲基和卤素; m选自0、1、2、3和4，并可以选择性地用最多两个独立选择的C1-6烷基取代; n选自0、1和2; p选自0、1和2; 或其药学上可接受的盐或溶剂，以及它们作为药物的用途，特别是作为p38激酶抑制剂。
• Medicament for treatment of liver cancer
  申请人：Zender Lars

  公开号：US10441577B2

  公开（公告）日：2019-10-15

  The invention provides a pharmaceutical composition comprising Sorafenib in combination with an inhibitor of a specific kinase inhibitor as a medicament for the treatment or prevention of liver cancer.

  本发明提供了一种药物组合物，该组合物由索拉非尼与一种特异性激酶抑制剂组合而成，作为治疗或预防肝癌的药物。
• 2' -METHYL-5-(1,3,4-OXADIAZOL-2-YL)-1,1'-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS
  申请人：GLAXO GROUP LIMITED

  公开号：EP1435949A1

  公开（公告）日：2004-07-14